Rolvedon Injection, Solution
Product Images NDC 76961-101

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Rolvedon (NDC 76961-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Spectrum Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duration Of Severe Neutropenia (dsn) Graphs (Image 01)

Two bar charts presenting the duration in days of severe neutropenia during Cycle 1 from two studies, comparing Rolvedon and Pegfilgrastim. Study 1 (n=406) shows patient percentages across no severe neutropenia, 1 to 3 days, and ≥4 days. Study 2 (n=237) displays similar data up to 3 days and ≥4 days, with percentages indicated for each category.*

FDA Label Image

Rolvedon Prefilled Syringe (Image 05)

An illustration of a syringe-like device designed for subcutaneous injection, showing internal components such as a plunger and a needle cover. This is consistent with the delivery apparatus for Rolvedon (eflapegrastim-xnst) injection, solution.*

FDA Label Image

Figure A (Image 06)

Instructional diagram showing components and usage steps for a prefilled syringe used with Rolvedon (eflapegrastim-xnst) injection. The diagram labels syringe parts including needle cap, needle, finger grip, viewing window, plunger rod, plunger head, needle guard, and needle guard clips, illustrating the syringe before and after use with emphasis on needle safety features.*

FDA Label Image

Figure B (Image 07)

An instructional illustration showing a hand placing a rectangular box into the upper section of an open refrigerator, indicating storage of the product under refrigeration conditions.*

FDA Label Image

Figure C (Image 08)

An instructional illustration showing a box with the expiration date location highlighted and an eye pointing towards it, indicating where to find the expiration date on the product packaging.*

FDA Label Image

Figure D (Image 16)

An illustration of a stopwatch showing the instruction to wait 30 minutes. The stopwatch face is partially shaded, emphasizing the 30-minute wait time.*

FDA Label Image

Figure E (Image 17)

Illustration showing four items commonly used in injection or wound care: a cotton ball, alcohol wipes in small packets, a sterile gauze pad in packaging, and a red sharps disposal container labeled 'SHARPS CONTAINER.'*

FDA Label Image

Figure F (Image 18)

Illustration showing a hand holding the Rolvedon 13.2 mg/0.6 mL subcutaneous injection syringe by the indicated grip area. The syringe is being removed or positioned above a molded plastic tray designed to hold the injection device securely.*

FDA Label Image

Figure G (Image 19)

Illustration showing a hand holding a prefilled syringe for Rolvedon (eflapegrastim-xnst) injection. The syringe is labeled with pointers indicating a viewing window and the expiration date on the label, demonstrating how to check the medication before use.*

FDA Label Image

Figure H (Image 09)

Illustration showing recommended subcutaneous injection sites on the body front and back. Labeled areas suitable for injection include the outer upper arm, abdomen, upper outer thigh, and upper outer buttock. The front and back views of a human figure highlight these areas with shaded regions.*

FDA Label Image

Figure I (Image 20)

An instructional illustration showing a hand applying a small adhesive bandage or gauze pad onto a forearm, depicting a step in subcutaneous injection site care.*

FDA Label Image

Figure J (Image 10)

An instructional illustration showing a pair of hands holding a syringe and removing the cap from the needle. The syringe appears to be prepared for use, with an arrow indicating the removal direction of the needle cap.*

FDA Label Image

Figure K (Image 11)

An instructional diagram showing the correct angle for subcutaneous injection using a syringe. The syringe is held by a hand above an arm, demonstrating the needle insertion angle between 45 and 90 degrees.*

FDA Label Image

Figure L (Image 12)

Illustration showing a hand administering a subcutaneous injection with a syringe. The syringe is held with the thumb pressing down on the plunger, indicated by a black arrow, near the injection site on the skin. This diagram depicts the injection technique relevant to subcutaneous administration.*

FDA Label Image

Figure M (Image 13)

Illustration showing a hand holding a prefilled injection device, pressing down to administer a subcutaneous injection. The image highlights the 'click' sound made during activation, with the needle positioned against the skin.*

FDA Label Image

Figure N (Image 14)

An instructional illustration showing a hand holding and removing the safety cap from a prefilled syringe for subcutaneous injection, depicting proper preparation of the Rolvedon injection, solution (eflapegrastim-xnst) 13.2 mg/.6mL.*

FDA Label Image

Figure O (Image 15)

An illustration showing the proper disposal of a syringe after use with the needle cap removed. The image depicts a hand holding a syringe and placing it into a red sharps container labeled "SHARPS CONTAINER." The needle cap is shown separate from the syringe, indicating it should not be reattached before disposal.*

FDA Label Image

Syringe Label (Image 02)

Rolvedon (eflapegrastim-xnst) injection label showing strength 13.2 mg/0.6 mL. The label indicates manufacture by Spectrum Pharmaceuticals, Inc. It includes a barcode and numeric code supporting product identification.*

FDA Label Image

Blister Tray Label (Image 03)

Label of Rolvedon (eflapegrastim-xnst) injection 13.2 mg/0.6 mL, a sterile, preservative-free solution for subcutaneous injection in a single-dose pre-filled 0.6 mL syringe. The label includes storage instructions (36°F to 46°F, protect from light, do not freeze or shake), manufacturer Spectrum Pharmaceuticals, Inc., and NDC 76961-101-01.*

FDA Label Image

Carton Labeling (Image 04)

Rolvedon 13.2 mg/0.6 mL (eflapegrastim-xnst) injection carton label for subcutaneous use. The label features the brand and generic names, dosage strength, administration route, and usage instructions. The labeler is Spectrum Pharmaceuticals, Inc., with storage instructions and a barcode visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.